Format

Send to

Choose Destination
J Pain Palliat Care Pharmacother. 2016 Jun;30(2):124-7. doi: 10.3109/15360288.2016.1173756. Epub 2016 May 12.

The Use of Transdermal Buprenorphine in Complex Regional Pain Syndrome: A Report of Two Cases.

Abstract

Management of complex regional pain syndrome (CRPS) can be challenging. Various pharmacological approaches have produced mixed results. Buprenorphine activates mu-opioid receptors and antagonizes kappa and delta receptors, acts at N-methyl-d-aspartate (NMDA) receptor, and is an orphan-related ligand-1 receptor agonist. It is available in transdermal patches that last for up to 7 days. This report describes two patients with refractory CRPS who were treated with transdermal buprenorphine. The patients experienced approximately 50% reduction in pain intensity scores. Application site rash that occurred was managed with topical steroid spray used before applying the patch.

KEYWORDS:

Butrans; buprenorphine; buprenorphine transdermal system; causalgia; complex regional pain syndrome; regional sympathetic dystrophy

PMID:
27172230
DOI:
10.3109/15360288.2016.1173756
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center